Nitazoxanide and COVID-19: A review

[1]  Junfen Fan,et al.  Molnupiravir and Its Antiviral Activity Against COVID-19 , 2022, Frontiers in Immunology.

[2]  Engy Elekhnawy,et al.  The potential application of probiotics for the prevention and treatment of COVID-19 , 2022, Egyptian Journal of Medical Human Genetics.

[3]  A. Rossi,et al.  Impairment of SARS-CoV-2 spike glycoprotein maturation and fusion activity by nitazoxanide: an effect independent of spike variants emergence , 2021, Cellular and Molecular Life Sciences.

[4]  Linding Wang,et al.  A Review of SARS-CoV2: Compared With SARS-CoV and MERS-CoV , 2021, Frontiers in Medicine.

[5]  Ashwag S Alanazi,et al.  Promising Antiviral Activity of Agrimonia pilosa Phytochemicals against Severe Acute Respiratory Syndrome Coronavirus 2 Supported with In Vivo Mice Study , 2021, Pharmaceuticals.

[6]  Hayder M Al-kuraishy.  Brain and Peripheral Neuronal Injury in Covid-19: The Panorama and Dispute , 2021, Applied Medical Research.

[7]  Engy Elekhnawy,et al.  Present and future treatment strategies for coronavirus disease 2019 , 2021, Future Journal of Pharmaceutical Sciences.

[8]  M. Shakibaei,et al.  Flavonoids against the SARS-CoV-2 induced inflammatory storm , 2021, Biomedicine & Pharmacotherapy.

[9]  K. Akarid,et al.  The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong? , 2021, Microbial Pathogenesis.

[10]  Ali I. Al-Gareeb,et al.  Case Report: Hyperbilirubinemia in Gilbert Syndrome Attenuates Covid-19-Induced Metabolic Disturbances , 2021, Frontiers in Cardiovascular Medicine.

[11]  A. El-Gilany,et al.  Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID‐19 , 2021, Journal of medical virology.

[12]  B. Baradaran,et al.  The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV , 2021, Archives of virology.

[13]  A. Bhargava,et al.  HPTLC analysis of Fumaria parviflora (Lam.) methanolic extract of whole plant , 2021, Future Journal of Pharmaceutical Sciences.

[14]  J. M. Bravo-San Pedro,et al.  Targeting Autophagy to Counteract Obesity-Associated Oxidative Stress , 2021, Antioxidants.

[15]  P. Pelosi,et al.  Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial , 2020, European Respiratory Journal.

[16]  A. Owen,et al.  Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2? , 2020, ACS infectious diseases.

[17]  Z. Dong,et al.  AMPK/mTOR Signaling in Autophagy Regulation During Cisplatin-Induced Acute Kidney Injury , 2020, Frontiers in Physiology.

[18]  F. Cadegiani,et al.  Hydroxychloroquine, nitazoxanide and ivermectin have similar effects in early COVID-19: a head-to-head comparison of the Pre-AndroCoV Trial. , 2020 .

[19]  S. Bhattacharyya,et al.  Role of Oxidative Stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) Infection: A Review , 2020, The Protein Journal.

[20]  Shijian Zhang,et al.  Spike Glycoprotein and Host Cell Determinants of SARS-CoV-2 Entry and Cytopathic Effects , 2020, Journal of Virology.

[21]  D. Kwiatkowski,et al.  mTORC1 hyperactivation in lymphangioleiomyomatosis leads to ACE2 upregulation in type II pneumocytes: implications for COVID-19 , 2020, European Respiratory Journal.

[22]  L. Sağlam,et al.  Evaluation of alpha defensin, IL‐1 receptor antagonist, and IL‐18 levels in COVID‐19 patients with macrophage activation syndrome and acute respiratory distress syndrome , 2020, Journal of medical virology.

[23]  T. Cavero,et al.  IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study , 2020, Journal of Allergy and Clinical Immunology.

[24]  H. Mendieta Zerón,et al.  Nitazoxanide against COVID-19 in three explorative scenarios. , 2020, Journal of infection in developing countries.

[25]  S. Biswas,et al.  Small Non-coding RNAs: Do They Encode Answers for Controlling SARS-CoV-2 in the Future? , 2020, Frontiers in Microbiology.

[26]  A. Singh,et al.  Identification of promising antiviral drug candidates against non-structural protein 15 (NSP15) from SARS-CoV-2: an in silico assisted drug-repurposing study , 2020, Journal of biomolecular structure & dynamics.

[27]  Nicolas Carlier,et al.  Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients , 2020, Science.

[28]  M. Khatri,et al.  Nitazoxanide/Camostat combination for COVID-19: An unexplored potential therapy , 2020 .

[29]  P. Martins-Filho,et al.  Potential role for nitazoxanide in treating SARS-CoV-2 infection , 2020, American journal of physiology. Lung cellular and molecular physiology.

[30]  Hayder M Al-Kuraishy,et al.  Macrolides and COVID-19: An optimum premise , 2020 .

[31]  Daniel J Klionsky,et al.  Canonical and Noncanonical Autophagy as Potential Targets for COVID-19 , 2020, Cells.

[32]  Shaoying Huang,et al.  The cytokine storm and COVID‐19 , 2020, Journal of medical virology.

[33]  T. Swartz,et al.  Targeting the NLRP3 Inflammasome in Severe COVID-19 , 2020, Frontiers in Immunology.

[34]  I. Barr,et al.  Host-targeted Nitazoxanide has a high barrier to resistance but does not reduce the emergence or proliferation of oseltamivir-resistant influenza viruses in vitro or in vivo when used in combination with oseltamivir. , 2020, Antiviral research.

[35]  H. Zerón,et al.  Treatment with Hydroxychloroquine vs Hydroxychloroquine + Nitazoxanide in COVID-19 patients with risk factors for poor prognosis: A structured summary of a study protocol for a randomised controlled trial , 2020, Trials.

[36]  T. Hussain.  Faculty Opinions recommendation of Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. , 2020 .

[37]  Vandna,et al.  Therapeutic potential of Nitazoxanide against Newcastle disease virus: A possible modulation of host cytokines , 2020, Cytokine.

[38]  Mina T. Kelleni.  Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management , 2020, Pharmacological Research.

[39]  Longxiang Xie,et al.  Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV , 2020, Viruses.

[40]  Ying Tang,et al.  Tizoxanide Inhibits Inflammation in LPS-Activated RAW264.7 Macrophages via the Suppression of NF-κB and MAPK Activation , 2019, Inflammation.

[41]  C. Bréchot,et al.  A Pilot Clinical Trial of Nitazoxanide in the Treatment of Chronic Hepatitis B , 2019, Hepatology communications.

[42]  Dirk E. Smith,et al.  Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists That Fully Bronchodilate Airways , 2018, bioRxiv.

[43]  M. Peppelenbosch,et al.  Nitazoxanide Inhibits Human Norovirus Replication and Synergizes with Ribavirin by Activation of Cellular Antiviral Response , 2018, Antimicrobial Agents and Chemotherapy.

[44]  T. Yip,et al.  Advancements in Host-Based Interventions for Influenza Treatment , 2018, Front. Immunol..

[45]  N. Berry,et al.  Second-generation nitazoxanide derivatives: thiazolides are effective inhibitors of the influenza A virus. , 2018, Future medicinal chemistry.

[46]  A. Hurt,et al.  The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide , 2017, Antiviral research.

[47]  V. Pascual,et al.  Influenza vaccines differentially regulate the interferon response in human dendritic cell subsets , 2017, Science Translational Medicine.

[48]  S. Tulsankar,et al.  Pharmacokinetics, Metabolism, and Partial Biodistribution of "Pincer Therapeutic" Nitazoxanide in Mice following Pulmonary Delivery of Inhalable Particles. , 2017, Molecular pharmaceutics.

[49]  J. Rossignol.  Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus , 2016, Journal of Infection and Public Health.

[50]  J. Rossignol.  Nitazoxanide: A first-in-class broad-spectrum antiviral agent , 2014, Antiviral Research.

[51]  H. Soufy,et al.  Effect of Egyptian Propolis on Lipid Profile and Oxidative Status in Comparison with Nitazoxanide in Immunosuppressed Rats Infected with Cryptosporidium spp. , 2014 .

[52]  Jianchao Wei,et al.  Nitazoxanide inhibits the replication of Japanese encephalitis virus in cultured cells and in a mouse model , 2014, Virology Journal.

[53]  Chang-Seon Song,et al.  Nitazoxanide suppresses IL-6 production in LPS-stimulated mouse macrophages and TG-injected mice. , 2012, International immunopharmacology.

[54]  Karen K. Y. Lam,et al.  Nitazoxanide Stimulates Autophagy and Inhibits mTORC1 Signaling and Intracellular Proliferation of Mycobacterium tuberculosis , 2012, PLoS pathogens.

[55]  M. Karin,et al.  Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage , 2011, Annals of the rheumatic diseases.

[56]  C. Lineweaver,et al.  Cancer tumors as Metazoa 1.0: tapping genes of ancient ancestors , 2011, Physical biology.

[57]  L. Saravolatz,et al.  Nitazoxanide: a new thiazolide antiparasitic agent. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[58]  R. Lins,et al.  Nitazoxanide: pharmacokinetics and metabolism in man. , 2000, International journal of clinical pharmacology and therapeutics.

[59]  L. Dubreuil,et al.  In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms , 1996, Antimicrobial agents and chemotherapy.